EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Evaluation of Vancomycin Therapeutic Drug Monitoring Strategies: Pharmacokinetic, Pharmacogenetic, and Clinical Perspectives in a Prospective, Real-World Cohort Study

İlker Kurt, Esen Gül Koçak, Meliha Şen, Bilgül Mete, Gökhan Aygün, Özkan Özdemir, Mehmet Güven Günver, Yalım Dikmen, Ömer Fehmi Tabak, B Sönmez Uydeş Doğan, Zeliha Pala Kara

European Journal of Clinical Pharmacology · 2026

DOI: 10.1007/s00228-026-04103-w ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift European Journal of Clinical Pharmacology, 2026. Verfasst von İlker Kurt und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Pharmacy, Istanbul University, Istanbul, Türkiye. Hauptthemen laut MEDLINE: Vancomycin, Drug Monitoring, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Istanbul University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Vancomycin therapeutic drug monitoring is essential for optimizing efficacy and reducing the risk of vancomycin-associated acute kidney injury (VA-AKI). Although recent guidelines recommend the ratio of area under the curve over 24 h to minimum inhibitory concentration (AUC 24 /MIC)–based monitoring over trough concentration-based monitoring, differences between AUC 24 /MIC estimation methods (e.g., pharmacokinetic equations and Bayesian approaches) may influence therapeutic classification in clinical practice. In addition, pharmacogenetic factors contributing to interindividual variability in vancomycin exposure remain incompletely characterized.

Methods

This prospective, single-center cohort study included adult patients who received intravenous vancomycin for at least 72 h between June 2024 and April 2025. Vancomycin trough and peak plasma concentrations were measured using an enzyme-linked immunosorbent assay. AUC 24 /MIC values were calculated using pharmacokinetic equation and Bayesian method. Agreement in therapeutic classification between trough concentration–based and AUC 24 /MIC-based monitoring was assessed. Associations between the rs2789047 genetic variant and relevant parameters were also evaluated.

Results

Thirty-six patients were included, of whom 38.9% developed VA-AKI. Despite strong correlations between trough concentration and AUC 24 /MIC values ( r = 0.84–0.87), substantial discordance in therapeutic classification was observed, with agreement rates of 63.9% for pharmacokinetic equation-based and 66.7% for Bayesian-based compared with trough concentration-based monitoring. In contrast, pharmacokinetic equation-based and Bayesian-based methods demonstrated strong concordance (86.1%). Higher trough concentrations and AUC 24 /MIC values were significantly associated with VA-AKI ( p < 0.001). Carriers of rs2789047 A-allele exhibited higher trough concentrations and reduced elimination rates.

Conclusion

Trough concentration-based monitoring frequently misclassified vancomycin exposure compared with AUC 24 /MIC–based approaches. Pharmacogenetic variability may further influence vancomycin exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VancomycinDrug MonitoringAnti-Bacterial AgentsHumansFemaleMaleProspective StudiesMiddle AgedArea Under CurveAgedAcute Kidney InjuryMicrobial Sensitivity TestsPharmacogeneticsBayes TheoremAdult

Stichwörter der Autor:innen

Acute kidney injuryPharmacogeneticPharmacokineticTherapeutic drug monitoringVancomycin

Substanzen

VancomycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Pharmacy, Istanbul University, Istanbul, Türkiye.
  • Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye.
  • Department of Medical Biology, Faculty of Medicine, Acibadem University, Istanbul, Türkiye.
  • Department of Biostatistics, Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
  • Department of Anesthesiology and Reanimation, Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye.
  • Department of Pharmacology, Faculty of Pharmacy, Istanbul University, Istanbul, Türkiye. zpala@istanbul.edu.tr.

Förderung

  • Istanbul University

Zitieren

APA

Kurt, İ., Koçak, E. G., Şen, M., Mete, B., Aygün, G., Özdemir, Ö., Günver, M. G., Dikmen, Y., Tabak, Ö. F., Uydeş Doğan, B. S., & Pala Kara, Z. (2026). Evaluation of Vancomycin Therapeutic Drug Monitoring Strategies: Pharmacokinetic, Pharmacogenetic, and Clinical Perspectives in a Prospective, Real-World Cohort Study. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-026-04103-w

Vancouver

Kurt İ, Koçak EG, Şen M, Mete B, Aygün G, Özdemir Ö, et al. Evaluation of Vancomycin Therapeutic Drug Monitoring Strategies: Pharmacokinetic, Pharmacogenetic, and Clinical Perspectives in a Prospective, Real-World Cohort Study. European Journal of Clinical Pharmacology. 2026. doi:10.1007/s00228-026-04103-w

BibTeX
@article{Kurt2026,
  author = {Kurt, İlker and Koçak, Esen Gül and Şen, Meliha and Mete, Bilgül and Aygün, Gökhan and Özdemir, Özkan and Günver, Mehmet Güven and Dikmen, Yalım and Tabak, Ömer Fehmi and Uydeş Doğan, B Sönmez and Pala Kara, Zeliha},
  title = {Evaluation of Vancomycin Therapeutic Drug Monitoring Strategies: Pharmacokinetic, Pharmacogenetic, and Clinical Perspectives in a Prospective, Real-World Cohort Study},
  journal = {European Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1007/s00228-026-04103-w}
}
Kostenlos starten →